XSU-T -0.22 SOLQ-T -0.79 SVR-T 0.36 MAL-T 0.28 CHTR-Q 1.95 IDT-N -0.7 FI-N 0.53
Daily Stock Opinions and Ratings
Stockchase Opinions

Jonathen Wellum, B. Comm, B. Sc Teva Pharmaceutical TEVA-N BUY Feb 22, 2001

Likes the generic drug sector as patent expirations are coming. Global. Good cash flow
Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. Sc
Unknown
Unlock Rating
$58.500

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

DON'T BUY

Teva Pharmaceutical(TEVA-N)

Aug 15, 2019
They went from an in incredibly well managed drug company and then management decided to develop their own drugs and make mistakes. It is difficult to unwind these problems. Turning around a company like this will be difficult because of the debt. This is a highly speculative stock.
Lorne SteinbergLorne Steinberg
No
Unlock Rating
$6.160

Stock price when the opinion was issued

biotechnology pharmaceutical
HOLD

Teva Pharmaceutical(TEVA-N)

Nov 28, 2019
Generic brand companies like Teva have struggled in the last 5 years has they competed with each others. Pfizer is in the process of buying one of their competitors and the Pfizer stock dropped 5$ on the announcement. Doesn't own Teva, purchased United Heatlth recently. You can hold but it's not a name he would hold due to the risk and they have no value added.
Bruce MurrayBruce Murray
No
Unlock Rating
$10.450

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

Teva Pharmaceutical(TEVA-N)

Feb 27, 2020
It's time to get back in. They all went crazy and then slid on sympathy when valiant went bust. There is tremendous value here. His model price is $21.26 or 63% upside. They presented earnings and the balance sheet looks great.
Brian Acker, CABrian Acker, CA
Unknown
Unlock Rating
$12.210

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA-N)

Oct 19, 2020

Doesn't offer growth. The stock is weak and will stay weak.

Jim Cramer - Mad MoneyJim Cramer - Mad Money
Unknown
Unlock Rating
$9.290

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA-N)

Apr 15, 2021
Involved in the opiate crisis. Balance sheet is weak. Overall topline growth is low. Stay away. A lot of problems still to overcome.
Christine PooleChristine Poole
No
Unlock Rating
$10.845

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA-N)

Nov 11, 2021
Tends to avoid companies with a ton of debt. Management missteps, and investors are paying for those. In the depths of a tough turnaround. He'd rather own a VTRS, where the debt is manageable, balance sheet's in better shape, with a better growth trajectory.
Lorne SteinbergLorne Steinberg
No
Unlock Rating
$9.545

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA-N)

Mar 17, 2022
He's put the white flag up on this one. It's about macro interest rates, currency moves. Don't waste your time with these story stocks. His model price is $18.80, and it could have all the fundamentals, but the macro waves swamp the boat. Go with the big names.
Brian Acker, CABrian Acker, CA
No
Unlock Rating
$7.805

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY ON WEAKNESS

Teva Pharmaceutical(TEVA-N)

Jan 06, 2023
Has owned company for a long period of time in the past. Previous reasons for owning stock not present anymore. Waiting to see if new drugs are invented/patented.
David FingoldDavid Fingold
Unknown
Unlock Rating
$10.520

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA-N)

Aug 04, 2023

Massive share price appreciation not sustainable. 
Large debt load presents difficulties.
Does not own shares.
Would not recommend buying at this time. 

Lorne SteinbergLorne Steinberg
Unknown
Unlock Rating
$9.745

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA-N)

Jan 05, 2024

It's cheap and has momentum, but that's all it has now. It never grabbed him.

Jim Cramer - Mad MoneyJim Cramer - Mad Money
No
Unlock Rating
$11.330

Stock price when the opinion was issued

biotechnology pharmaceutical

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

VHI-T -0.15$12.6
AFRM-Q 8.47$88.46
XID-T -0.62$53.17
EMMF-N 0$
UMAX-T -0.13$13.59

Today's Top Picks

XSU-T -0.22$44.85
SOLQ-T -0.79$22.05
SVR-T 0.36$18.91
MAL-T 0.28$15.94
CHTR-Q 1.95$265.58

Popular Articles

Latest Sell Signals

HMAX-T 0.055$14.99
WSM-N 0.13$188.19
CSU-T 128.41$4550.34
COST-Q -1.64$943.32
FICO-N 15.27$1521.64

Most Recent Experts

Mike Philbrick

Mike Philbrick

ReSolve Asset Management

Stockchase Insights

Stockchase Insights

5i Research

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: hello@stockchase.com.

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© Stockchase Inc. by Wealthica